Novel strategies to target inflammatory processes in atherosclerosis

Current Pharmaceutical Design

Volumn 19, Issue 9, 2013, Pages 1616-1625

  Imanishi, Toshio ^a   Akasaka, Takashi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Chemokines; Cytokines; Inflammation; Oxidative stress; Vulnerable plaque

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; CD14 ANTIGEN; CD16 ANTIGEN; CD36 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 5; L SELECTIN; METHOTREXATE; PADGEM PROTEIN; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TOCILIZUMAB; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; B LYMPHOCYTE; CELL DIFFERENTIATION; CHOLESTEROL TRANSPORT; CYTOKINE PRODUCTION; DISEASE COURSE; ENDOPLASMIC RETICULUM STRESS; HUMAN; INSULIN RESISTANCE; MACROPHAGE; MONOCYTE; NONHUMAN; OBESITY; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; STABLE ANGINA PECTORIS;

EID: 84876734839     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213805219685     Document Type: Article

References (123)

1. Hasnson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
2. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-26.
3. Tabas I. The role of endoplasmic reticulum stress in the progression of atherosclerosis. Circ Res 2010; 107: 839-50.
4. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 2010; 10: 36-46.
5. Martinet W, Schrijvers DM, De Meyer GR. Pharmacological modulation of cell death in atherosclerosis: a promising approach towards plaque stabilization? Br J Pharmacol 2011; 164: 1-13.
6. Nhan TQ, Liles WC, Schwartz SM. Role of caspases in death and survival of the plaque macrophage. Arterioscler Thromb Vas Biol 2005; 25: 895-903.
7. Burke AP, Farb A, Malcon GT, Liang Y, Smialek JE, Virmani R. Plaque rupture and sudden death related to exertion in men with coronary artery disease: JAMA 1999; 281: 921-6.
8. Shah PK. Mechanisms of plaque vulnerability and ruptures. J. Am. Coll. Cardiol 2003; 41: 15S-22S.
9. Shah PK. Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Vasc Med 1998; 3: 199-206.
10. Mestas J, Ley K. Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovascular Med 2008; 18: 228-32.
11. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscle Thromb Vasc Biol 2007; 27: 2292-301.
12. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71-82.
13. Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117: 195-205.
14. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-64.
15. Bazan JF, Baco KB, Hardiman G, et al. A new class of membranebound chemokine with a CX3C motif. Nature 1997; 385: 640-4.
16. Fong AM, Robinson LA, Steeber DA, et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J. Exp. Med 1998; 188: 1413-9.
17. Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91: 521-30.
18. Shantsila E, Lip GY. Monocyte diversity in myocardial infarction. J Am Coll Cardiol 2009; 54: 139-42.
19. Swirski FK, Weissleder R, Pittet MJ. Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29: 1424-32.
20. Mosig S, Rennert K, Krause S, et al. Different functions of monocyte subsets in familial hypercholesterolemia: potential function of CD14+ CD16+ monocytes in detoxification of oxidized LDL. FASEB J 2009; 23: 866-74.
21. Belge KU, Dayyani F, Horelt A, et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 2002; 168: 3536-42.
22. Cros J, Cagnard N, Woollard K, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010; 33: 375-86.
23. Johnson JL, Newby AC. Macrophage heterogeneity in atherosclerotic plaques. Curr Opin Lipidol 2009; 20(5): 370-8.
24. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscl Thromb Vasc Biol 2009; 29: 1419-23.
25. Frantz S, Ertl G, Bauersachs J. Mechanisms of diseases: Toll-like receptors in cardiovascular disease. Nat Clin Prac.2007; 4: 444-54.
26. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373-84.
27. Healy AM, Pickard MD, Pradhan AD, et al. Platelet expression profiling and clinical validation of Myeloid-Related Protein-14 as a novel determinant of cardiovascular events. Circulation 2006; 113: 2278-84.
28. Morrow DA, Wang Y, Croce K, et al. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombosis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J 2008; 155: 49-55.
29. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Ciculation 2005; 111: 2654-61.
30. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev 2006; 86: 515-81
31. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
32. Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferon-β enhances atherosclerosis in apolipoprotein E-/-mice. Am. J. Pathol 2000; 157: 1819-624.
33. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res.2002; 90: 251-62.
34. Moore KJ, Tabas I. Macropahges in the pathogenesis of atherosclerosis. Cell 2011; 145: 341-55.
35. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010; 11: 155-61.
36. Tabas I, Ron D. Molecular mechanisms integrating pathways of endoplasmic reticulum-stress-induced apoptosis. Nat Cell Biol 2011; 13: 184-90.
37. Myoishi M, Hao H, Minamino T, et al. Increased endoplasmic reticulum stress in atherosclerotic plaques associated with acute coronary syndrome. Circulation 2007; 116: 1226-33.
38. Timmins JM, Ozcan L, Seimon TA, et al. Calcium/calmodulindependent protein kinase II links endoplasmic reticulum stress with Fas and mitochondrial apoptosis pathways. J Clin Invest 2009; 119: 2925-94.
39. Zhang TY, McGillicuddy FC, Hinkle CC, et al. Adipocyte modulation of high-density lipoprotein cholesterol. Circulation 2010; 121: 1347-55.
40. Rothblat AR, Phillips MC. High-density lipoprotein heterogeneity and function in reverse transport. Current Opinion in Lipidology 2010; 21: 229-38.
41. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: inplications for the treatment of atherosclerosis. Cell Metabolism 2008; 7: 363-75.
42. Yvan-Charvet L, Ranalletta M, Wang N, et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis. J Clin Invest 2007; 117: 3900-8.
43. Terasaka N, Yu S, Yvan-Charvet L, et al. ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest 2008; 118: 3701-13.
44. Terasaka N, Westerterp M, Koetsveld J, et al. ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveorin-1 and endothelial NO synthase. Arterioscler Thromb Vasc Biol 2010; 30: 2219-25.
45. Spieker LE, Sudano I, Hürlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105: 1399-402.
46. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003; 107: 2944-8.
47. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-22.
48. Shah PK. Mechanisms of plaque vulnerability and ruptures. J Am Coll Cardiol 2003; 41: 15S-22S.
49. Shah PK. Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Vasc Med1998; 3: 199-206.
50. Stone GW, Maehara A, Lansky AJ, et al. A prospective naturalhistory study of coronary atherosclerosis. N Engl J Med 2011; 364: 226-35.
51. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-82.
52. Burke AP, Farb A, Malcom GT, Liang Y, Smialek JE, Virmani R. Plaque rupture and sudden death related to exertion in men with coronary artery disease. JAMA 1999; 281: 921-6.
53. Hansson GK. Mechanisms of disease-Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
54. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-9.
55. Choudhary S, Higgins CL, Chen IY, et al. Quantitation and localization of matrix metalloproteinases and their inhibitors in human carotid endarterectomy tissues. Arterioscler Thromb Vasc Biol 2006; 26: 2351-8.
56. Sluijter JP, Pulskens WP, Schoneveld AH, et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 2006; 37: 235-9.
57. Blankenberg S, Rupprecht HJ, Poirier O, et al. AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579-85.
58. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1,-2,-3, and-9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003; 23: 769-75.
59. Imanishi T, Han DK, Hofstra L, et al. Apoptosis of vascular smooth muscle cells is induced by Fas ligand derived from monocytes/ macrophage. Atherosclerosis 2002; 161: 143-51.
60. Imanishi T, Hano T, Nishio I. Liles WC, Schwartz SM, Han DK. Transition of apoptotic resistant vascular smooth muscle cells to troptotic sensitive state is correlated with downregulation of c-FLIP. J Vasc Res 2000; 37: 523-31.
61. Harris LK, Keogh RJ, Wareing M, et al. Invasive trophoblasts stimulate vascular smooth muscle cell apoptosis by a fas liganddependent mechanism Am J Pathol 2006; 169: 1863-74.
62. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 2010; 10: 36-46.
63. Thorp E, Cui D, Schrijvers DM, Kraiakose G, Tabas I. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe-/-mice. Arterioscler Thromb Vasc Biol 2008; 28: 1421-8.
64. Ait-Oufella H, Pouresmail V, Simon T, et al. Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. Arteroscler Thromb Vasc Biol 2008; 28: 1429-31.
65. Sahter S, et al. Blood 2007; 109: 1026-33.
66. Han S, Liang CP, deVries-seimon T, et al. Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. Cell Metab 2006; 3: 257-66.
67. Kashiwagi M, Imanishi T, Tsujioka H, et al. Association of monocyte subsets with vulnerability characteristics of coronary plaques as assessed by 64-slice multidetector computed tomography in patients with stable angina pectoris. Atherosclerosis 2010; 212: 171-6.
68. Ikejima H, Imanishi T, Tsujioka H, et al. Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris. Circ J 2010; 74: 337-45.
69. Swirski FK, Weissleder R, Pittet MJ. Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29: 1424-32.
70. Rothe G, Gabriel H, Kovacs E, et al. Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol., 1996, 16, 1437-47.
71. Moatti D, Faure S, Fumeron F, et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 2001; 97: 1925-8.
72. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of circulating Toll-like receptor 4-positve monocytes in patients with acute coronary syndrome. Circulation 2005; 111: 2654-61.
73. Kashiwagi M, Imanishi T, Ozaki Y, et al. Differential expression of Toll-like receptor 4 and human monocyte subsets in acute myocardial infarction. Atherosclerosis 2012; 221: 249-53.
74. Wyss CA, Neidhart M, Altwegg L, et al. Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes. Eur Heart J 2010; 31: 1457-69.
75. Gerlis LM. The significance of adventitial infiltrations in coronary atherosclerosis. Br Heart J 1956; 18: 166-72.
76. Ait-Oufella H, Herbin O, Bouaziz JD, et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 2010; 207: 1579-87.
77. Kyaw T, Tay C, Khan A, et al. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol 2010; 185: 4410-9.
78. Sage AP, Tsiantoulas D, Baker L, et al. BAFF receptor reduces the development of atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2012; 32: 1573-6.
79. Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt-Supprian M. TNF family member B cell-activating factor (BAFF) receptordependent and-independent roles for BAFF in B cell physiology. J immunol 2004; 173: 2245-52.
80. Binder CJ, Shaw PX, Chang MK, et al. The role of natural antibodies in atherogenesis. J Lipid Res 2005; 46: 1353-63.
81. Binder CJ, Chang MK, Shaw PX, et al. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8: 1218-26.
82. Nilsson J, Hansson GK. Autoimmunity in atherosclerosis: a protective response losing control? J Intern Med 2008; 263: 464-478.
83. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995; 92: 821-5.
84. Ameli S, Hultgårdh-Nilsson A, Regnström J, et al. Effect of immunization with homologous LDL and oxidized LDL on early athero sclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996; 16: 1074-9.
85. Zhou X, Caligiuri G, Hamsten A, Lefvert AK, Hansson GK. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arteriosscler Thromb Vasc Biol 2001; 21: 108-14.
86. Nilsson J, Hansson GK, Shah PK. Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler Thromb Vasc Biol 2005; 25: 18-28.
87. Fredrikson GN, Hedblad B, Berglund G, et al. Identification of immune responses against aldehyde-modified peptide sequences in apo B-100 associated with cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23: 872-8.
88. Fredrikson GN, Söderberg I, Lindholm M, et al. Inhibition of atherosclerosis in ApoE-Null mice by immunization with ApoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 2003; 23: 879-84.
89. Chyu KY, Zhao X, Reyes OS, et al. Atheroprotective immunization using Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholeserolemic apo E(-/-) mice. Biochem Biophy Res Commun 2005; 338: 1982-9.
90. Fredrikson GN, Andersson L, Söderberg I, et al. Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific anibody expression. Autoimmunity 2005; 38: 171-9.
91. Foteinos G, Afzal AR, Mandal K, Jahangiri M, Xu Q. Anti-heat shock protein 60 autoantibodies induce atherosclerosis in apolipoprotein E-deficient mice via endothelial damage. Circulation 2005; 112: 1206-13.
92. Benagiano M, D'Elios MM, Amedei A, et al. Human 60-kDa heat shock protein is a target autoantigen of T cells derived from atherosclerotic plaques. J Immunol 2005; 174: 6017-509.
93. van Puijvelde GH, van Es T, van Wanrooij EJ, et al. Induction of oral tolerance to HSP60 or an HSP60-peptide ctivates T cell regulation and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2677-83.
94. Lu X, Chen D, Endresz V, et al. Immunization with a combination of apoB and HSP60 epitopes significantly reduces early atherosclerotic lesion inApobtm25gyLdlrtm1Her/Jmice.
95. Ray KK, Cannon CP. The potential relevance of the multiple lipidindependent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005; 46: 1425-33.
96. Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, Cachofeiro V. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins.
97. Tian XY, Wong WT, Xu A, et al. Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress. Br J Pharmacol 2011; 164: 598-606.
98. Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol 2005; 96: 61F-68F.
99. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in Creactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-82.
100. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thisckness. N Engl J Med 2009; 361: 2113-22.
101. Lukasova M, Malaval C, Gille A, Kero J, Offermanns S. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest 2011; 121: 1163-73.
102. Steinberg D, Glass CK, Witztum JL. Evidence mandating earlier and more aggressive treatment of hypercholesterolemia. Circulation 2008; 118: 672-7.
103. Potteaux S, Gautier EL, Hutchinson SB, et al. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/-mice during disease regression. J Clin Invest 2011; 121: 2025-36.
104. Feig JE, Pineda-Torra I, Sanson M, et al. LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J Clin Invest 2010; 120: 4415-24.
105. Mestas J, Ley K. Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc Med 2008; 18: 228-32.
106. Weitzum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med 2001; 11: 93-102.
107. Williams KJ, Fisher EA. Oxidation, lipoproteins, and atherosclerosis: which is wrong, the antioxidants or the theory? Curr Opin Clin Nutr Metab Care 2005; 8: 139-146.
108. Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol 2002; 15: 439-46.
109. Tabas I. The role of endoplasmic reticulum stress in the progression of atherosclerosis. Circ Res 2010; 107: 839-50.
110. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 2010; 10: 36-46.
111. Erbay E, Babaev VR, Mayers JR, et al. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med 2009; 15: 1383-91.
112. Wilensky RL, Shi Y, Mohler ER 3rd, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med.2008; 14: 1059-66.
113. Serruys PW, García-García HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008; 118: 1172-82.
114. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350: 1505-15.
115. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-22.
116. Stroes ES, Nierman MC, Meulenberg JJ, et al. Intramuscler administration of A AV1-lipoprotein lipase S447 lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 2008; 28: 2303-4.
117. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pahrmacol 2008; 154: 1465-73.
118. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-1 Milano on coronary atherosclerosis in patients with acute coronary syndormes: a randomized controlled trial. JAMA 2003; 290: 2292-300.
119. Navab M, Shechter I, Anantharamaiah GM, et al. Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol 2010; 30: 164-8.
120. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.
121. Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32(7): 1213-8.
122. Dixon WG, Watson KD, Lunt M, Hyrich KL. Reducion in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56: 2905-12.
123. Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011; 13: R141.